Literature DB >> 20392683

Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study.

Jeremy Dale1, Steven Martin, Roger Gadsby.   

Abstract

PURPOSE OF STUDY: To evaluate the 3-year impact of initiating basal insulin on glycaemic control (HbA1c) and weight gain in patients with poorly controlled type 2 diabetes registered with UK general practices that volunteered to participate in an insulin initiation training programme.
METHODS: Audit utilising data collected from practice record systems, which included data at baseline, 3, 6 months and subsequent six-monthly intervals post-insulin initiation for up to 10 patients per participating practice.
RESULTS: Of 115 eligible practices, 55 (47.8%) contributed data on a total of 516 patients. The mean improvement in HbA1c levels in the first 6 months was 1.4% (range -3.8% to 8.2%, median=1.40%). Thereafter, there was no overall change in HbA1c levels, although the change for individual patients ranged from -4.90% to +7.50%. At 36 months, 141 (41%) patients for whom data were provided had achieved the pre-2006/2007 UK Quality and Outcomes Framework (QOF) target of 7.4% or less, including 98 (29%) who had achieved an HbA1c of 7% or less. Patients who achieved target had a lower HbA1c at baseline (mean 9.1% compared to 9.7%; p<0.001); had a lower weight at 36 months (mean 88.0kg compared to 93.5kg; p=0.05); were more likely to be on basal insulin alone (88, 47.1% compared to 46, 34.6%; p<0.05); and were slightly older (mean 64.5 years compared to 61.7 years; p<0.05).
CONCLUSION: Attending an insulin initiation training programme may successfully prepare primary healthcare professionals to initiate insulin therapy as part of everyday practice for patients with poorly controlled type 2 diabetes. The impact on glycaemic control is maintained over a 3-year period. Although intensification of treatment occurred during this period, the findings suggest scope for further intensification of insulin therapy in order to improve on the glycaemic control achieved during the first 6 months post-insulin initiation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20392683     DOI: 10.1016/j.pcd.2010.03.001

Source DB:  PubMed          Journal:  Prim Care Diabetes        ISSN: 1878-0210            Impact factor:   2.459


  21 in total

1.  Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting.

Authors:  Alex Ramírez-Rincón; Carlos E Builes-Montaño; Jaime A Hincapié-García; Victor M Blanco; José F Botero-Arango
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

Review 2.  Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues.

Authors:  Allan Vaag; Søren S Lund; Sørens Lund
Journal:  Eur J Endocrinol       Date:  2011-09-19       Impact factor: 6.664

3.  An exploratory trial of insulin initiation and titration among patients with type 2 diabetes in the primary care setting with retrospective continuous glucose monitoring as an adjunct: INITIATION study protocol.

Authors:  Irene D Blackberry; John S Furler; Louise E Ginnivan; Hanan Derraz; Alicia Jenkins; Neale Cohen; James D Best; Doris Young; Danny Liew; Glenn Ward; Jo-Anne Manski-Nankervis; David N O'Neal
Journal:  BMC Fam Pract       Date:  2014-05-03       Impact factor: 2.497

4.  Engaging GPs in insulin therapy initiation: a qualitative study evaluating a support program in the Belgian context.

Authors:  Patricia Sunaert; Sara Willems; Luc Feyen; Hilde Bastiaens; Jan De Maeseneer; Lut Jenkins; Frank Nobels; Emmanuel Samyn; Marie Vandekerckhove; Johan Wens; An De Sutter
Journal:  BMC Fam Pract       Date:  2014-08-21       Impact factor: 2.497

5.  Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes.

Authors:  Michael D Feher; John Brazier; Nicolaas Schaper; Gabriela Vega-Hernandez; Annie Nikolajsen; Mette Bøgelund
Journal:  BMJ Open Diabetes Res Care       Date:  2016-04-29

6.  Can primary care team-based transition to insulin improve outcomes in adults with type 2 diabetes: the stepping up to insulin cluster randomized controlled trial protocol.

Authors:  John S Furler; Doris Young; James Best; Elizabeth Patterson; David O'Neal; Danny Liew; Jane Speight; Leonie Segal; Carl May; Jo-Anne Manski-Nankervis; Elizabeth Holmes-Truscott; Louise Ginnivan; Irene D Blackberry
Journal:  Implement Sci       Date:  2014-02-14       Impact factor: 7.327

7.  Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.

Authors:  H W Rodbard; J B Buse; V Woo; T Vilsbøll; I H Langbakke; K Kvist; S C L Gough
Journal:  Diabetes Obes Metab       Date:  2015-11-05       Impact factor: 6.577

8.  Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study.

Authors:  Cheli Melzer Cohen; Brian Larsen Thorsted; Michael Lyng Wolden; Gabriel Chodick; Avraham Karasik
Journal:  Diabetes Ther       Date:  2017-09-07       Impact factor: 2.945

Review 9.  Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.

Authors:  Virginia Valentine; Jennifer Goldman; Jay H Shubrook
Journal:  Diabetes Ther       Date:  2017-07-18       Impact factor: 2.945

10.  Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system.

Authors:  Marek Psota; Maria Bucek Psenkova; Natalia Racekova; Antonio Ramirez de Arellano; Tom Vandebrouck; Barnaby Hunt
Journal:  Clinicoecon Outcomes Res       Date:  2017-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.